PMID- 28736315
OWN - NLM
STAT- MEDLINE
DCOM- 20171004
LR  - 20181113
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 187
IP  - 10
DP  - 2017 Oct
TI  - The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.
PG  - 2139-2151
LID - S0002-9440(17)30206-7 [pii]
LID - 10.1016/j.ajpath.2017.03.016 [doi]
AB  - Triple-negative breast cancer is viewed clinically as an aggressive subgroup of
      breast cancer. In fact, most triple-negative breast cancers are poor-prognosis
      tumors with a complex genomic landscape. However, triple-negative disease is
      vastly heterogeneous, encompassing multiple entities with marked genetic,
      transcriptional, histologic, and clinical differences, with neoplasms in this
      group ranging from low to high grade. Among the less common low-grade
      triple-negative lesions, two large subgroups, both with a rather indolent
      behavior, can be distinguished: a low-grade triple-negative breast neoplasia
      family, which includes nonobligate precursors of triple-negative breast cancer,
      and, despite being low-grade, harbors the complex genomic landscape of usual
      triple-negative breast cancer, and the salivary gland-like tumors of the breast, 
      lacking all the cardinal molecular features of conventional triple-negative
      breast cancer and underpinned by specific fusion genes or hotspot mutations,
      which may be of diagnostic and possibly therapeutic utility. Progression to
      high-grade triple-negative breast cancer likely occurs in both subgroups but at
      different rates. In this review, we describe the heterogeneity of triple-negative
      disease, focusing on the histologic and molecular features of the low-grade
      lesions. Recognition that triple-negative breast cancer is an operational term
      and that triple-negative disease is heterogeneous and includes low-grade forms
      driven by distinct sets of genetic alterations is germane to the successful
      implementation of precision medicine.
CI  - Copyright (c) 2017 American Society for Investigative Pathology. Published by
      Elsevier Inc. All rights reserved.
FAU - Geyer, Felipe C
AU  - Geyer FC
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Pareja, Fresia
AU  - Pareja F
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Weigelt, Britta
AU  - Weigelt B
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York.
FAU - Rakha, Emad
AU  - Rakha E
AD  - Department of Pathology, Nottingham University, Nottingham, United Kingdom.
FAU - Ellis, Ian O
AU  - Ellis IO
AD  - Department of Pathology, Nottingham University, Nottingham, United Kingdom.
FAU - Schnitt, Stuart J
AU  - Schnitt SJ
AD  - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical
      School, Boston, Massachusetts. Electronic address: sschnitt@bwh.harvard.edu.
FAU - Reis-Filho, Jorge S
AU  - Reis-Filho JS
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New
      York. Electronic address: reisfilj@mskcc.org.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20170720
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
SB  - AIM
SB  - IM
MH  - Biological Evolution
MH  - Cell Differentiation
MH  - Female
MH  - Humans
MH  - Neoplasm Grading
MH  - Triple Negative Breast Neoplasms/genetics/*pathology
PMC - PMC5809519
EDAT- 2017/07/25 06:00
MHDA- 2017/10/05 06:00
CRDT- 2017/07/25 06:00
PHST- 2017/02/09 00:00 [received]
PHST- 2017/03/27 00:00 [accepted]
PHST- 2017/07/25 06:00 [pubmed]
PHST- 2017/10/05 06:00 [medline]
PHST- 2017/07/25 06:00 [entrez]
AID - S0002-9440(17)30206-7 [pii]
AID - 10.1016/j.ajpath.2017.03.016 [doi]
PST - ppublish
SO  - Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 
      2017 Jul 20.